373 related articles for article (PubMed ID: 17987222)
1. Nilotinib therapy in chronic myelogenous leukemia.
Quintas-Cardama A; Cortes J
Drugs Today (Barc); 2007 Oct; 43(10):691-702. PubMed ID: 17987222
[TBL] [Abstract][Full Text] [Related]
2. Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.
Quintás-Cardama A; Cortes J
Future Oncol; 2008 Oct; 4(5):611-21. PubMed ID: 18922118
[TBL] [Abstract][Full Text] [Related]
3. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
4. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
6. Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
Fullmer A; Kantarjian H; Cortes J; Jabbour E
Expert Opin Pharmacother; 2010 Dec; 11(18):3065-72. PubMed ID: 21073351
[TBL] [Abstract][Full Text] [Related]
7. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
[TBL] [Abstract][Full Text] [Related]
8. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
Hazarika M; Jiang X; Liu Q; Lee SL; Ramchandani R; Garnett C; Orr MS; Sridhara R; Booth B; Leighton JK; Timmer W; Harapanhalli R; Dagher R; Justice R; Pazdur R
Clin Cancer Res; 2008 Sep; 14(17):5325-31. PubMed ID: 18765523
[TBL] [Abstract][Full Text] [Related]
9. Therapy options in imatinib failures.
Ramirez P; DiPersio JF
Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
[TBL] [Abstract][Full Text] [Related]
10. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
von Bubnoff N; Manley PW; Mestan J; Sanger J; Peschel C; Duyster J
Blood; 2006 Aug; 108(4):1328-33. PubMed ID: 16614241
[TBL] [Abstract][Full Text] [Related]
11. Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.
Breccia M; Alimena G
Curr Drug Targets; 2009 Jun; 10(6):530-6. PubMed ID: 19519355
[TBL] [Abstract][Full Text] [Related]
12. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Hughes T; Saglio G; Branford S; Soverini S; Kim DW; Müller MC; Martinelli G; Cortes J; Beppu L; Gottardi E; Kim D; Erben P; Shou Y; Haque A; Gallagher N; Radich J; Hochhaus A
J Clin Oncol; 2009 Sep; 27(25):4204-10. PubMed ID: 19652056
[TBL] [Abstract][Full Text] [Related]
13. Targeted drugs in chronic myeloid leukemia.
Gora-Tybor J; Robak T
Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
[TBL] [Abstract][Full Text] [Related]
14. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
15. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Maekawa T; Ashihara E; Kimura S
Int J Clin Oncol; 2007 Oct; 12(5):327-40. PubMed ID: 17929114
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
Jiang H; Chen SS; Jiang B; Jiang Q; Qin YZ; Lai YY; Liu YR; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):123-6. PubMed ID: 22730663
[TBL] [Abstract][Full Text] [Related]
17. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
DeAngelo DJ; Attar EC
Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
[TBL] [Abstract][Full Text] [Related]
18. Nilotinib for the treatment of chronic myeloid leukemia.
Kim TD; Dörken B; le Coutre P
Expert Rev Hematol; 2008 Oct; 1(1):29-39. PubMed ID: 21083005
[TBL] [Abstract][Full Text] [Related]
19. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Erba HP; Pham DC; Zaiden R; Vu H; Tai S
Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576
[TBL] [Abstract][Full Text] [Related]
20. Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
Bauer RC; Sänger J; Peschel C; Duyster J; von Bubnoff N
Clin Cancer Res; 2013 Jun; 19(11):2962-72. PubMed ID: 23549879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
